tbuckley/cabot-search huggingface dataset:
Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’
Authors: Yuri Muraviov, Ludmila Muraviova
Journal: Annals of the Rheumatic Diseases (2020)

Our interest in correspondence of Ruscitti et al focusing on the analysis of the data of the multicentre double-blind randomised placebo-controlled trial assessing the efficacy and safety of canakinumab in patients with adult-onset Still’s disease (AOSD) can be explained by the authors’ astonishing assumption stating that the clinical trial by Kedor et al “… is a further example of how the absence of validated measures could impair the expected positive results, despite the strong scientific rationale.”1 2 Ruscitti et al seriously believe that changing the measurement units will change the results of the trial; therefore, a specific AOSD activity score is required immediately.1 Kedor et al used the DAS28 to assess the disease activity, selecting patients with active joint involvement as previously …
ASSESSMENT OF 479 PATIENTS WITH AUTOIMMUNE LIVER DISEASES ACCORDING TO THE IAIHG SCORING SYSTEM FOR AUTOIMMUNE HEPATITIS DOES NOT SUPPORT THE CONTENTION OF OVERLAP SYNDROMES AS SEPARATE DIAGNOSTIC ENTITIES
Authors: K M Boberg, A W Lohse, E M Hennes, H P Dienes, E J Heathcote, R W Chapman, E Schrumpf
Journal: Hepatology (2009)
Delayed Antibiotic Prescriptions—Reply
Authors: Theresa Rowe, Jeffrey A. Linder
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Authors: Annika Nelde, Tatjana Bilich, Jonas S. Heitmann, Yacine Maringer, Helmut R. Salih, Malte Roerden, Maren Lübke, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hörber, Bjoern Traenkle, Philipp D. Kaiser, Ulrich Rothbauer, Matthias Becker, Daniel Junker, Gérard Krause, Monika Strengert, Nicole Schneiderhan-Marra, Markus F. Templin, Thomas O. Joos, Daniel J. Kowalewski, Vlatka Stos-Zweifel, Michael Fehr, Armin Rabsteyn, Valbona Mirakaj, Julia Karbach, Elke Jäger, Michael Graf, Lena-Christin Gruber, David Rachfalski, Beate Preuß, Ilona Hagelstein, Melanie Märklin, Tamam Bakchoul, Cécile Gouttefangeas, Oliver Kohlbacher, Reinhild Klein, Stefan Stevanović, Hans-Georg Rammensee, Juliane S. Walz
Journal: Nature Immunology (2020)
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Authors: Zsofia D. Drobni, Raza M. Alvi, Jana Taron, Amna Zafar, Sean P. Murphy, Paula K. Rambarat, Rayma C. Mosarla, Charlotte Lee, Daniel A. Zlotoff, Vineet K. Raghu, Sarah E. Hartmann, Hannah K. Gilman, Jingyi Gong, Leyre Zubiri, Ryan J. Sullivan, Kerry L. Reynolds, Thomas Mayrhofer, Lili Zhang, Udo Hoffmann, Tomas G Neilan
Journal: Circulation (2020)

Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events.
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference
Authors: Marlies Ostermann, Alexander Zarbock, Stuart Goldstein, Kianoush Kashani, Etienne Macedo, Raghavan Murugan, Max Bell, Lui Forni, Louis Guzzi, Michael Joannidis, Sandra L. Kane-Gill, Matthieu Legrand, Ravindra Mehta, Patrick T. Murray, Peter Pickkers, Mario Plebani, John Prowle, Zaccaria Ricci, Thomas Rimmelé, Mitchell Rosner, Andrew D. Shaw, John A. Kellum, Claudio Ronco
Journal: JAMA Network Open (2020)

<h3>Importance</h3> In the last decade, new biomarkers for acute kidney injury (AKI) have been identified and studied in clinical trials. Guidance is needed regarding how best to incorporate them into clinical practice. <h3>Objective</h3> To develop recommendations on AKI biomarkers based on existing data and expert consensus for practicing clinicians and researchers. <h3>Evidence Review</h3> At the 23rd Acute Disease Quality Initiative meeting, a meeting of 23 international experts in critical care, nephrology, and related specialties, the panel focused on 4 broad areas, as follows: (1) AKI risk assessment; (2) AKI prediction and prevention; (3) AKI diagnosis, etiology, and management; and (4) AKI progression and kidney recovery. A literature search revealed more than 65 000 articles published between 1965 and May 2019. In a modified Delphi process, recommendations and consensus statements were developed based on existing data, with 90% agreement among panel members required for final adoption. Recommendations were graded using the Grading of Recommendations, Assessment, Development and Evaluations system. <h3>Findings</h3> The panel developed 11 consensus statements for biomarker use and 14 research recommendations. The key suggestions were that a combination of damage and functional biomarkers, along with clinical information, be used to identify high-risk patient groups, improve the diagnostic accuracy of AKI, improve processes of care, and assist the management of AKI. <h3>Conclusions and Relevance</h3> Current evidence from clinical studies supports the use of new biomarkers in prevention and management of AKI. Substantial gaps in knowledge remain, and more research is necessary.
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Authors: R.E. Miller, A. Leary, C.L. Scott, V. Serra, C.J. Lord, D. Bowtell, D.K. Chang, D.W. Garsed, J. Jonkers, J.A. Ledermann, S. Nik-Zainal, I. Ray-Coquard, S.P. Shah, X. Matias-Guiu, E.M. Swisher, L.R. Yates
Journal: Annals of Oncology (2020)
Covid-19: 120 million rapid tests pledged to low and middle income countries
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Covid-19: 120 million rapid tests pledged to low and middle income countries Elisabeth MahaseLow and middle income countries have been pledged 120 million covid-19 diagnostic tests, which can provide results in 15 to 30 minutes, by a group of organisations including the Bill and Melinda Gates Foundation and the World Health Organization.
The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother–neonate cohort study
Authors: Xianglin Wei, Juan Yang, Lidong Gao, Lili Wang, Qiaohong Liao, Qi Qiu, Kaiwei Luo, Shuanbao Yu, Yonghong Zhou, Fengfeng Liu, Qi Chen, Juanjuan Zhang, Bingbing Dai, Hao Yang, Jiaxin Zhou, Weijia Xing, Xinhua Chen, Min He, Lingshuang Ren, Jinxin Guo, Li Luo, Peng Wu, Zhiyong Chen, H Rogier van Doorn, Simon Cauchemez, Benjamin J Cowling, Hongjie Yu
Journal: The Lancet Infectious Diseases (2020)
Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (vol 74, e177, 209)
Authors: DK Arnett, RS Blumenthal, MA Albert, AB Buroker, ZD Goldberger, EJ Hahn, CD Himmelfarb, A Khera, D Lloyd-Jones, JW McEvoy, ED Michos, Miedema, D Munoz, Smith, SS Virani, KA Williams, J Yeboah, B Ziaeian
Journal: Journal of the American College of Cardiology (2020)
Association Between Left Ventricular Noncompaction and Vigorous Physical Activity
Authors: Jose A. de la Chica, Sandra Gómez-Talavera, Jose M. García-Ruiz, Ines García-Lunar, Belén Oliva, Juan M. Fernández-Alvira, Beatriz López-Melgar, Javier Sánchez-González, José L. de la Pompa, Jose M. Mendiguren, Vicente Martínez de Vega, Antonio Fernández-Ortiz, Javier Sanz, Leticia Fernández-Friera, Borja Ibáñez, Valentín Fuster
Journal: Journal of the American College of Cardiology (2020)

Left ventricular (LV) hypertrabeculation fulfilling noncompaction cardiomyopathy criteria has been detected in athletes. However, the association between LV noncompaction (LVNC) phenotype and vigorous physical activity (VPA) in the general population is disputed. The aim of this study was to assess the relationship between LVNC phenotype on cardiac magnetic resonance (CMR) imaging and accelerometer-measured physical activity (PA) in a cohort of middle-aged nonathlete participants in the PESA (Progression of Early Subclinical Atherosclerosis) study. In PESA participants (n = 4,184 subjects free of cardiovascular disease), PA was measured by waist-secured accelerometers. CMR was performed in 705 subjects (mean age 48 ± 4 years, 16% women). VPA was recorded as total minutes per week. The study population was divided into 6 groups: no VPA and 5 sex-specific quintiles of VPA rate (Q1 to Q5). The Petersen criterion for LVNC was evaluated in all subjects undergoing CMR. For participants meeting this criterion (noncompacted-to-compacted ratio ≥2.3), 3 more restrictive LVNC criteria were also evaluated (Jacquier, Grothoff, and Stacey). LVNC phenotype prevalence according to the Petersen criterion was significantly higher among participants in the highest VPA quintile (Q5 = 30.5%) than in participants with no VPA (14.2%). The Jacquier and Grothoff criteria were also more frequently fulfilled in participants in the highest VPA quintile (Jacquier Q5 = 27.4% vs. no VPA = 12.8% and Grothoff Q5 = 15.8% vs. no VPA = 7.1%). The prevalence of the systolic Stacey LVNC criterion was low (3.6%) and did not differ significantly between no VPA and Q5. In a community-based study, VPA was associated with a higher prevalence of CMR-detected LVNC phenotype according to diverse established criteria. The association between VPA and LVNC phenotype was independent of LV volumes. According to these data, vigorous recreational PA should be considered as a possible but not uncommon determinant of LV hypertrabeculation in asymptomatic subjects.
Impact of COVID-19 on accident and emergency attendances and emergency and planned hospital admissions in Scotland: an interrupted time-series analysis
Authors: Rachel H Mulholland, Rachael Wood, Helen R Stagg, Colin Fischbacher, Jaime Villacampa, Colin R Simpson, Eleftheria Vasileiou, Colin McCowan, Sarah J Stock, Annemarie B Docherty, Lewis D Ritchie, Utkarsh Agrawal, Chris Robertson, Josephine LK Murray, Fiona MacKenzie, Aziz Sheikh
Journal: Journal of the Royal Society of Medicine (2020)

Following the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and the subsequent global spread of the 2019 novel coronavirus disease (COVID-19), health systems and the populations who use them have faced unprecedented challenges. We aimed to measure the impact of COVID-19 on the uptake of hospital-based care at a national level.The study period (weeks ending 5 January to 28 June 2020) encompassed the pandemic announcement by the World Health Organization and the initiation of the UK lockdown. We undertook an interrupted time-series analysis to evaluate the impact of these events on hospital services at a national level and across demographics, clinical specialties and National Health Service Health Boards.Scotland, UK.Patients receiving hospital care from National Health Service Scotland.Accident and emergency (A&E) attendances, and emergency and planned hospital admissions measured using the relative change of weekly counts in 2020 to the averaged counts for equivalent weeks in 2018 and 2019.Before the pandemic announcement, the uptake of hospital care was largely consistent with historical levels. This was followed by sharp drops in all outcomes until UK lockdown, where activity began to steadily increase. This time-period saw an average reduction of -40.7% (95% confidence interval [CI]: -47.7 to -33.7) in A&E attendances, -25.8% (95% CI: -31.1 to -20.4) in emergency hospital admissions and -60.9% (95% CI: -66.1 to -55.7) in planned hospital admissions, in comparison to the 2018-2019 averages. All subgroup trends were broadly consistent within outcomes, but with notable variations across age groups, specialties and geography.COVID-19 has had a profoundly disruptive impact on hospital-based care across National Health Service Scotland. This has likely led to an adverse effect on non-COVID-19-related illnesses, increasing the possibility of potentially avoidable morbidity and mortality. Further research is required to elucidate these impacts.
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Authors: James C. Lee, Sadaf Mehdizadeh, Jennifer Smith, Arabella Young, Ilgiz A. Mufazalov, Cody T. Mowery, Adil Daud, Jeffrey A. Bluestone
Journal: Science Immunology (2020)

Liver metastasis suppresses systemic tumor-specific immunity and contributes to the resistance to checkpoint immunotherapy.
IL-6 Trans-Signaling Definesa New Asthma Phenotype Associated with Frequent Exacerbations, Increased Airway Inflammation and Impaired Epithelial Integrity
Authors: H Olsson, Z Jevnikar, J Ostling, E Ax, K Thorn, L Oberg, M Van Geest, O Vaarala, A Singhania, A James, S Wilson, T S Hinks, P H Howarth, Grp U-Biopreds.
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients.
Authors: BC Yoo, JH Kim, KS Lee, TH Kim, SW Paik, SH Ryu, Jy Han, M Cho, SG Hwang, Bi Kim, YS Lee, HC Kim, JS Hwang, SK Choi, YS Kim, YO Kweon, Jy Choi, HY Lee, HW Yoo, MJ Otto, PA Furman, HS Lee
Journal: Hepatology (2018)
Autochthonous dengue in two Dutch tourists visiting Département Var, southern France, July 2020
Authors: Tom D Vermeulen, Johan Reimerink, Chantal Reusken, Sandra Giron, Peter J de Vries
Journal: Eurosurveillance (2020)

We report dengue virus (DENV) infection in two Dutch tourists who visited Département Var, southern France, in July and August 2020. As some autochthonous dengue cases have occurred in Europe in recent years, awareness among physicians and public health experts about possible intermittent presence of DENV in southern Europe is important to minimise delay in diagnosis and treatment. Quick diagnosis can lead to timely action to contain the spread of vector-borne diseases and minimise transmission.
Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma
Authors: Pei‐Suen Tsou, Pamela J. Palisoc, Nicholas A. Flavahan, Dinesh Khanna
Journal: Arthritis & Rheumatology (2020)

Intravenous iloprost improves Raynaud's phenomenon (RP) and promotes healing of digital ulcers in systemic sclerosis (SSc; scleroderma). Despite a short half-life, its clinical efficacy lasts weeks. Endothelial adherens junctions, which are formed by VE-cadherin clustering between endothelial cells (ECs), regulate endothelial properties including barrier function, endothelial-to-mesenchymal transition (EndoMT), and angiogenesis. We undertook this study to investigate the hypothesis that junctional disruption contributes to vascular dysfunction in SSc, and that the protective effect of iloprost is mediated by strengthening of those junctions.
Abstract IA24: Are there nonimmune targets in the BRAFV600 WT melanoma patient?
Authors: Jeffrey A. Sosman
Journal: Cancer Research (2020)

Abstract Molecular targeting of melanoma beyond the BRAFV600 mutation has been a frustrating and largely unsuccessful pursuit. The dominant driver in many of these cases is the gain of function NRAS mutations, while a smaller subset are in part driven by NF1 loss of function genetic alterations, and lastly a subset (WT) with a variety of mutations, most of which activate the MAPK pathway such as mutations in c-Kit, MEK, KRAS, HRAS, and alternate non-V600 BRAF mutations. This effort has concentrated on the inhibition of the activated MAPK pathway with MEK inhibitors and targeted NRAS tumors, which make at least 1/3 of the non-BRAF V600 mutant melanoma. As a single agent this approach has been disappointing, but preclinical data support the need for combination therapy, including MEK inhibition with inhibition of alternate pathways such as the PI3/Akt pathway, the cell cycle pathway with CDK4/6 inhibitors, or MDM2 inhibitors to restore functional p53 driven apoptosis. These approaches have been frequently plagued by significant toxicity. Many of these approaches continue to be pursued in the clinic in the hope that different schedules will be more effective and less toxic. An obvious target has been inhibition of downstream pERK which has shown some limited clinical activity. Attacking other pathways looks promising, including targeting mitotic kinases, such as PLK1 and Aurora kinase A. Either inhibiting autophagy or enhancing Bim-directed apoptosis is also under investigation. Finally, we now have a better understanding about the interaction between the targeted agent and the tumor microenvironment. Preclinical and clinical studies show that MEK inhibition can actually enhance the T-cell response at the site of the tumor by selectively eliminating naïve T cells; CDK4/6 inhibition can influence PD-L1 expression and induce retroviral sequences, which then induce an inflammatory (hot) tumor microenvironment. On the other hand, there is further evidence that the microenvironment may be critical for targeted therapy to be effective. This supports an approach combining targeted agents with immune checkpoint inhibitors even in BRAF WT melanoma. While immunotherapy approaches dominate treatment of BRAF WT melanoma, it is critical that we do not lose focus on defining targets, developing better agents, and learning to administer them by an optimal schedule. Citation Format: Jeffrey A. Sosman. Are there nonimmune targets in the BRAFV600 WT melanoma patient? [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA24.
Abstract 16672: High Sensitivity Troponin I Measurement in Symptomatic Outpatients With Suspected Coronary Artery Disease: Results From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Study
Authors: James L Januzzi, Sunil Suchindran, Adrian Coles, Maros Ferencik, Manesh R Patel, Udo Hoffmann, Geoffrey S Ginsburg, Pamela S Douglas
Journal: Circulation (2017)

Introduction: Higher concentrations of troponin (Tn) I are associated with prevalent coronary artery disease (CAD) in patients with myocardial infarction. The meaning of TnI concentrations in less ...
The Productivity Requirements of Implementing a Medical Scribe Program
Authors: Tyler J. Miksanek, M. Reza Skandari, Sandra A. Ham, Wei Wei Lee, Valerie G. Press, Marie T. Brown, Neda Laiteerapong
Journal: Annals of Internal Medicine (2020)

Economic analyses of medical scribes have been limited to individual, specialty-specific clinics.To determine the number of additional patient visits various specialties would need to recover the costs of implementing scribes in their practice at 1 year.Modeling study based on 2015 data from the Centers for Medicare & Medicaid Services (CMS) and National Ambulatory Medical Care Survey. Scribe costs were based on literature review and a third-party contractor model. Revenue was calculated from direct visit billing, CPT (Current Procedural Terminology) billing, and data from the National Ambulatory Medical Care Survey.2015 data from CMS and the National Ambulatory Medical Care Survey.Health care providers.1 year.Office-based clinic.The number of additional patient visits a physician must have to recover the costs of a scribe program at 1 year.An average of 1.34 additional new patient visits per day (295 per year) were required to recover scribe costs (range, 0.89 [cardiology] to 1.80 [orthopedic surgery] new patient visits per day). For returning patients, an average of 2.15 additional visits per day (472 per year) were required (range, 1.65 [cardiology] to 2.78 [orthopedic surgery] returning visits per day). The addition of 2 new patient (or 3 returning) visits per day was profitable for all specialties.Results were not sensitive to most inputs, with the exception of hourly scribe cost and inclusion of CPT revenue.Use of Medicare data and failure to account for indirect costs, downstream revenue, or changes in documentation quality.For all specialties, modest increases in productivity due to scribes may allow physicians to see more patients and offset scribe costs, making scribe programs revenue-neutral.University of Chicago Medicine's Center for Healthcare Delivery Science and Innovation and the Bucksbaum Institute.
Rheumatic disease patients'preferences in adverse drug reaction information regarding biologics
Authors: G. Weits, L. Kosse, H. Vonkeman, P. Spuls, B. Van den Bemt, S. Tas, F. Hoentjen, M. Nurmohamed, M. Van Doorn, E. Van Puijenbroek, N. Jessurun
Journal: Annals of the Rheumatic Diseases (2020)